Skip to main content
Top
Published in: Strahlentherapie und Onkologie 1/2014

01-01-2014 | Original article

Brain metastasis from non-small cell lung cancer (NSCLC)

Prognostic importance of the number of involved extracranial organs

Authors: L. Gerdan, B. Segedin, V. Nagy, M.T. Khoa, N.T. Trang, S.E. Schild, D. Rades, M.D.

Published in: Strahlentherapie und Onkologie | Issue 1/2014

Login to get access

Abstract

Background and purpose

This study investigated the potential prognostic value of the number of involved extracranial organs in patients with brain metastasis from non-small cell lung cancer (NSCLC).

Material and methods

A total of 472 patients who received whole-brain radiotherapy (WBRT) alone with 5 × 4 Gy or 10 × 3 Gy for brain metastasis from NSCLC were included in this retrospective study. In addition to the number of involved extracranial organs, 6 further potential prognostic factors were investigated including WBRT regimen, age, gender, Karnofsky Performance Score (KPS), number of brain metastases, and the interval from cancer diagnosis to WBRT. Subgroup analyses were performed for patients with metastatic involvement of one (lung vs. bone vs. other metastasis) and two (lung + bone vs. lung + lymph nodes vs. other combinations) extracranial organs.

Results

The survival rates at 6 months of the patients with involvement of 0, 1, 2, 3, and ≥ 4 extracranial organs were 52, 27, 17, 4, and 14 %, respectively (p < 0.001). On multivariate analysis, the number of involved extracranial organs remained significant (risk ratio 1.32; 95 % confidence interval 1.19–1.46; p < 0.001). Age < 65 years (p = 0.004), KPS ≥ 70 (p < 0.001), and only 1–3 brain metastases (p = 0.022) were also significantly associated with survival in the multivariate analysis. In the separate analyses of patients with involvement of one and two extracranial organs, survival was not significantly different based on the pattern of extracranial organ involvement.

Conclusion

The number of involved extracranial organs is an independent prognostic factor of survival in patients with brain metastasis from NSCLC, irrespective of the pattern of extracranial organ involvement.
Literature
1.
go back to reference Chiou SM (2013) Survival of brain metastatic patients treated with gamma knife radiosurgery alone. Clin Neurol Neurosurg 115:276–284CrossRef Chiou SM (2013) Survival of brain metastatic patients treated with gamma knife radiosurgery alone. Clin Neurol Neurosurg 115:276–284CrossRef
2.
go back to reference Dziggel L, Segedin B, Podvrsnik NH et al (2013) Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189:364–366PubMedCrossRef Dziggel L, Segedin B, Podvrsnik NH et al (2013) Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol 189:364–366PubMedCrossRef
3.
go back to reference Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
4.
go back to reference Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295–1304PubMedCrossRef Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295–1304PubMedCrossRef
5.
6.
go back to reference Nieder C, Andratschke NH, Geinitz H et al (2012) Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. Strahlenther Onkol 188:692–695PubMedCrossRef Nieder C, Andratschke NH, Geinitz H et al (2012) Use of the Graded Prognostic Assessment (GPA) score in patients with brain metastases from primary tumours not represented in the diagnosis-specific GPA studies. Strahlenther Onkol 188:692–695PubMedCrossRef
7.
go back to reference Rades D, Bohlen G, Dunst J et al (2008) Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. Strahlenther Onkol 184:30–35PubMedCrossRef Rades D, Bohlen G, Dunst J et al (2008) Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases. Strahlenther Onkol 184:30–35PubMedCrossRef
8.
go back to reference Rades D, Küter JD, Gliemroth J et al (2012) Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis. Strahlenther Onkol 188:143–147PubMedCrossRef Rades D, Küter JD, Gliemroth J et al (2012) Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis. Strahlenther Onkol 188:143–147PubMedCrossRef
9.
go back to reference Rades D, Küter JD, Meyners T et al (2012) Single brain metastasis: resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. Clin Neurol Neurosurg 114:326–330PubMedCrossRef Rades D, Küter JD, Meyners T et al (2012) Single brain metastasis: resection followed by whole-brain irradiation and a boost to the metastatic site compared to whole-brain irradiation plus radiosurgery. Clin Neurol Neurosurg 114:326–330PubMedCrossRef
10.
go back to reference Rades D, Panzner A, Dziggel L et al (2012) Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118:3852–3859PubMedCrossRef Rades D, Panzner A, Dziggel L et al (2012) Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer 118:3852–3859PubMedCrossRef
11.
go back to reference Rades D, Schild SE, Lohynska R et al (2007) Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer 110:1077–1082PubMedCrossRef Rades D, Schild SE, Lohynska R et al (2007) Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer 110:1077–1082PubMedCrossRef
12.
go back to reference Vuong DA, Rades D, Eck AT van et al (2013) Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer’s perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg 115:276–284PubMedCrossRef Vuong DA, Rades D, Eck AT van et al (2013) Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer’s perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg 115:276–284PubMedCrossRef
13.
go back to reference Wen PY, Black PM, Loeffler JS (2001) Metastatic brain cancer. In: Vita V de, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th Edn. Lippincott, Williams & Wilkins. Philadelphia, 2655–2670 Wen PY, Black PM, Loeffler JS (2001) Metastatic brain cancer. In: Vita V de, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th Edn. Lippincott, Williams & Wilkins. Philadelphia, 2655–2670
Metadata
Title
Brain metastasis from non-small cell lung cancer (NSCLC)
Prognostic importance of the number of involved extracranial organs
Authors
L. Gerdan
B. Segedin
V. Nagy
M.T. Khoa
N.T. Trang
S.E. Schild
D. Rades, M.D.
Publication date
01-01-2014
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 1/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0439-6

Other articles of this Issue 1/2014

Strahlentherapie und Onkologie 1/2014 Go to the issue